Menu
Search
|

Menu

Close
X

GTX Inc GTXI.OQ (NASDAQ Stock Exchange Capital Market)

16.71 USD
+1.16 (+7.46%)
As of 2:29 AM IST
chart
Previous Close 15.55
Open 15.67
Volume 30,054
3m Avg Volume 13,820
Today’s High 16.91
Today’s Low 15.67
52 Week High 16.91
52 Week Low 2.77
Shares Outstanding (mil) 16.06
Market Capitalization (mil) 131.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.317
FY16
-1.204
FY15
-1.565
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
15.49
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-196.34
14.43
Return on Equity (TTM)
vs sector
-196.34
16.13

EXECUTIVE LEADERSHIP

Robert Wills
Executive Chairman of the Board, Since 2015
Salary: --
Bonus: --
Marc Hanover
Chief Executive Officer, Director, Since 2015
Salary: $393,317.00
Bonus: $127,828.00
Jason Shackelford
Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer, Since 2014
Salary: $199,365.00
Bonus: $26,250.00
Henry Doggrell
Vice President, Chief Legal Officer, Secretary, Since 2012
Salary: $363,576.00
Bonus: $63,626.00
Diane Young
Vice President, Chief Medical Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

175 Toyota Plz Fl 7
MEMPHIS   TN   38103-5601

Phone: +1901.2718622

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

SPONSORED STORIES